Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma.
Luke S McLeanAnnette M LimMathias BresselAlesha A ThaiDanny RischinPublished in: Drugs & aging (2024)
ICIs have demonstrated efficacy and have an acceptable safety profile among older patients with advanced CSCC, with comparable efficacy to what has been demonstrated in current clinical trials.